OTC and ornithine carbamoyltransferase deficiency: Using AAV8-mediated delivery of ExSpeU1 in a murine model of OTCD carrying the c.386G>A splice-site mutation, Balestra et al. (2020) demonstrated a significant increase in correctly spliced OTC transcripts, highlighting the in vivo potential of targeted splicing correction and its future relevance in preventing neurological complications.